NASDAQ:PSTV
Plus Therapeutics, Inc. Stock News
$1.72
-0.0205 (-1.18%)
At Close: May 01, 2024
Plus Therapeutics, Inc. (PSTV) Q4 2023 Earnings Call Transcript
07:07pm, Tuesday, 05'th Mar 2024
Plus Therapeutics, Inc. (NASDAQ:PSTV ) Q4 2023 Earnings Conference Call March 5, 2024 5:00 PM ET Company Participants Marc Hedrick - President and CEO Andrew Sims - CFO Norman LaFrance - CMO Conferenc
Plus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue Estimates
06:36pm, Tuesday, 05'th Mar 2024
Plus Therapeutics (PSTV) came out with a quarterly loss of $0.70 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to loss of $2.40 per share a year ago.
Penny Stocks To Buy Now? 4 To Watch Before Next Week
10:05am, Friday, 03'rd Nov 2023
Penny stocks, also known as micro-cap equities or stocks under $5 per share, offer investors affordable opportunities. This is to buy shares in emerging small companies early before potential growth a
Plus Therapeutics, Inc. (PSTV) Q3 2023 Earnings Call Transcript
07:46pm, Tuesday, 31'st Oct 2023
Plus Therapeutics, Inc. (NASDAQ:PSTV ) Q3 2023 Earnings Conference Call October 31, 2023 5:00 PM ET Corporate Participants Marc Hedrick - President and Chief Executive Officer Andrew Sims - Vice Presi
Plus Therapeutics to Present at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar
09:21am, Wednesday, 25'th Oct 2023
Update on the ReSPECT-GBM Trial, including Phase 2, with Rhenium-186 Obisbemeda in Recurrent Glioblastoma will be Presented at SNO Annual Meeting Update on the ReSPECT-GBM Trial, including Phase 2, wi
Plus Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on October 31, 2023
04:05pm, Monday, 23'rd Oct 2023
AUSTIN, Texas, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advan
AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with adva
Plus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
07:00am, Wednesday, 30'th Aug 2023
AUSTIN, Texas, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technolo
Plus Therapeutics, Inc. (PSTV) Q2 2023 Earnings Call Transcript
09:52pm, Monday, 14'th Aug 2023
Plus Therapeutics, Inc. (NASDAQ:PSTV ) Q2 2023 Earnings Conference Call August 14, 2023 5:00 PM ET Corporate Participants Marc Hedrick - President and Chief Executive Officer Andrew Sims - Chief Finan
Plus Therapeutics to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 14, 2023
04:05pm, Tuesday, 08'th Aug 2023
AUSTIN, Texas, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics
Plus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
07:00am, Thursday, 03'rd Aug 2023
AUSTIN, Texas, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advance
Plus Therapeutics to Present at the 2nd Annual Targeted Radiopharmaceuticals Summit
07:00am, Thursday, 13'th Jul 2023
AUSTIN, Texas, July 13, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advan
Plus Therapeutics to Present at the 2023 Virtual June Investor Summit
07:00am, Thursday, 25'th May 2023
AUSTIN, Texas, May 25, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanc
Plus Therapeutics, Inc. (PSTV) Q1 2023 Earnings Call Transcript
10:30pm, Thursday, 20'th Apr 2023
Plus Therapeutics, Inc. (PSTV) Q1 2023 Earnings Call Transcript.
Plus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue Estimates
07:01pm, Thursday, 20'th Apr 2023
Plus Therapeutics (PSTV) came out with a quarterly loss of $0.14 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.19 per share a year ago.